Kestrel

Send Away Test for Oncotype DX Breast Recurrence Score

Gloucestershire Hospitals NHS Foundation Trust · published Tue 3 Feb 2026

In plain English

Reading the notice and writing a summary. This takes a few seconds the first time.

The notice doesn't say where the documents are, but Gloucestershire Hospitals NHS Foundation Trust's other tenders use health-family.force.com. Register there (it's free) and look for this tender, or email the buyer's contact on the notice.

The notice as published

Provision of Oncotype DX Breast Recurrence Score testing which addresses the issue of overtreatment with chemotherapy, particularly for patients with lymph nod-positive breast cancer. This contract is to commission Exact Science to provide Oncotype DX Breast Recurrence Score which is a genomic assay that provides a personalised insight into an individual patients breast cancer biology. <br/>This contract has been awarded under Direct Award A <br/>The lifetime value of this contract is £214,650 <br/>The contract is in place from 1st July 2025 until 30th June 2026